Rituximab-Induced Hypogammaglobulinemia and Infection Risk in Multiple Sclerosis - Neurology Advisor
Reduced immunoglobulin G (IgG) levels were reported for almost a quarter of patients with multiple sclerosis (MS) treated with rituximab with a potential interaction between IgG level and the risk for infection, according to study findings published in Neurology Neuroimmunology & Neuroinflammation. The objective of the current study was to investigate the incidence of hypogammaglobulinemia and infections in patients with MS who were treated with rituximab in the MS center of Marseille, France. The prospective, observational study included 188 patients (mean age, 43.4 years; 118 women) with MS who were treated with rituximab. The median follow-up after the first rituximab infusion was 3.5 years (range 1–5.8 years), and the median number of rituximab infusions was 5 (range 1–9 infusions). Continue Reading Reduced levels of IgG <6 g/L were documented in 14 patients (7.4%) before the first infusion of rituximab and in 44 patients (23.4%) aft